Drug Design, Development and Therapy (Aug 2018)
Monitoring antiangiogenesis of bevacizumab in zebrafish
Abstract
Jing Zhang,1,2,* Beili Gao,1,* Wenchao Zhang,1 Zijun Qian,1 Yi Xiang1 1Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Institute of Respiratory Diseases, School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Respiratory Department of Shanghai East Hospital Affiliated to Tongji University, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: Bevacizumab, which is a humanized anti-VEGF antibody, has been successfully applied in clinics since 2004. Bevacizumab in combination with chemotherapy showed high safety and has been applied to solid tumors. However, studies on the insight into the mechanism about the antiangiogenesis activity of bevacizumab were mostly done on mice models, and so there are no visual and intuitive models to observe the process of antiangiogenesis. Here, we first used a zebrafish model to investigate the angiogenesis suppressing behavior of bevacizumab. Our results showed that bevacizumab inhibited formation of zebrafish subintestinal veins, which mimics the process of tumor angiogenesis in vivo. Meanwhile, bevacizumab caused specific vasculature formation defects in subintestinal veins but not in the trunk. Our study also indicated that bevacizumab could inhibit zebrafish retinal angiogenesis with therapeutic potential. Keywords: zebrafish, bevacizumab, anti-angiogenesis, VEGF, subintestinal vein
